RECOMBINANT ENVELOPE PROTEIN HIV1 F2 RGP120 WITH MF59

本研究的目的是确定安全性和免疫原性 CHO细胞衍生的HIV-1 SF-2 rgp 120的改进的两瓶制剂 当施用时，用MF 59佐剂乳剂配制的包膜疫苗 健康的HIV-1未感染志愿者。先前的制剂具有 稳定性欠佳或不切实际（需要在-70 ℃下储存 摄氏度）。因此，已经开发了一种改进的制剂， 预计将更加实用和稳定，以允许对此进行研究。 扩增的疫苗候选物或为其他目的设计的类似候选物 我们的目标是招募足够的志愿者， 随着他们的长期进步。

The objective of this study is to determine the safety and immunogenicity of an improved two-vial formulation of CHO cell-derived HIV-1 SF-2 rgp120 envelope vaccine formulated with MF59 adjuvant emulsion when administered to healthy HIV-1 uninfected volunteers. Prior formulations had suboptimal stability or were impractical (requiring storage at -70 degrees C). Therefore, an improved formulation has been developed that is expected to be more practical and stable, to allow studies of this expanded vaccine candidate or analogous candidates designed for other geographic regions.Our goal is recruitment of sufficient volunteers and following their long term progress.